All In Biotech

Drug Trial Radar · NCT05083468

The Safety, Tolerability, and Pharmacokinetics (PK) of SR750 in Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled, 2-part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SR750 in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

83

Actual

Start

Oct 29, 2021

Primary completion

Oct 14, 2022

Study completion Oct 14, 2022

Sponsor

Sponsor type
Industry
First posted
Oct 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety, tolerability, and PK of SR750 in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

  • SR750 tabletDrug

    The volunteers will be orally administrated by single or multiple dose of SR750 tablet with 240 mL water.

  • matching placeboDrug

    The volunteers will be orally administrated by single or multiple dose of matching placebo with 240 mL water.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The frequency and severity of AEs in healthy volunteers administrated with single and repeated oral doses of SR750Time frame: Up to Day15 for the safety follow up since Day1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Pty Ltd

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.